Nebraska Center for Molecular Target Discovery and Development
Nebraska Center for Molecular Target Discovery and Development
批准号:
10714236
负责人:
Robert E. Lewis
金额:
$230.25万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-03-16 至 2028-06-30
关键词:
AppointmentAwardAwarenessBasic ScienceBeliefBiologicalBiological ModelsBiologyBiomedical ResearchCareer MobilityCellsCenters of Research ExcellenceChemicalsClassificationClinicalCollaborationsDataData AnalysesData SetDedicationsDevelopmentDisciplineDiseaseEvaluationFacultyFinancial SupportFundingFutureGenerationsGenomicsGoalsGrantHealthHomeostasisHumanInfrastructureInstitutionInvestmentsJournalsMedical centerMentorsModernizationMolecularMolecular AnalysisMolecular TargetNebraskaOrganoidsPhasePre-Clinical ModelProtacReagentResearchResearch PersonnelResearch Project GrantsResearch SupportResource SharingResourcesSystemTaxesTeacher Professional DevelopmentTechniquesTechnologyTherapeuticTimeTrainingUniversitiesValidationVisionanalytical methodbench to bedsidecollegecostdata acquisitionexpectationexperiencefaculty supportgenetic analysisimprovedinhibitorinsightinterestmembernovelnovel therapeuticsoperationpreclinical developmentprogramsresearch and developmentskill acquisitionsmall moleculesuccesstechnology developmenttherapeutic developmenttherapeutic targettranscriptomicsundergraduate student
中文摘要
项目总结:总体
内布拉斯加州分子目标发现和开发中心(CMTDD)的目标是建立和
扩展内布拉斯加大学医学中心(UNMC)和
内布拉斯加州大学系统催化识别、验证和开发方法
与临床重要疾病有关的分子靶点的操纵。我们察觉到一种增长
期刊和授权机构对日益复杂的模型系统和数据集的期望。
获取这些系统和生成高内容数据通常需要大量的时间投资
以及对有限的研究资源征税的资金。提升CMTDD研究项目的竞争力
领导(RPL)和其他大学教员在第二阶段,CMTDD最近投资于
开发技术,以提高调查员研究的复杂性,同时最大限度地降低
进入。这些技术:单细胞和空间转录分析,有机物生成和
操纵、抑制和蛋白水解靶向嵌合体(PROTAC)的合成将整合成三个
第2阶段CMTDD核心。这些投资将增强该机构的研究能力,扩大
其教师的翻译能力,促进有前途的新员工的培训、指导和职业发展
,并有效地推动发现和发展,以改善内布拉斯加州和
这个国家。第二阶段RPL为CMTDD带来了广泛的尖端专业知识。带着指导和准备
使用CMTDD支持的核心,我们的RPL将成为自给自足的教员,对
军警部队未来的成功。我们的第二阶段RPL分享了对基本生物学原理的探索热情
这种不充分的细胞动态平衡以及许多疾病可以有效地分类和表征的信念
通过详细的基因组、遗传和分子分析确定驱动因素和漏洞
将出现独特的治疗方法。为了实现这一愿景,CMTDD将:1)保持行政
核心和指导计划,在年的头四年成功地完成了除一名以外的所有初始RPL
支持;2)通过新建立的最先进的单细胞科学核心提高研究能力
以及空间转录、有机物发育、抑制物和PROTAC的合成和验证;以及3)
提供低成本或免费获得这些技术和试剂,作为一种负担得起的手段,以提高
调查员研究的影响。
英文摘要
Project Summary: Overall
The goal of the Nebraska Center for Molecular Target Discovery and Development (CMTDD) is to establish and
expand physical and intellectual resources at the University of Nebraska Medical Center (UNMC) and the
University of Nebraska system to catalyze the identification, validation, and development of approaches for
manipulation of molecular targets implicated in clinically important diseases. We perceive an increasing
expectation by journals and granting agencies for progressively sophisticated model systems and data sets.
Acquisition of these systems and generation of high-content data often requires a substantial investment in time
and money that taxes limited research resources. To enhance the competitiveness of CMTDD Research Project
Leaders (RPLs) and other university faculty members during Phase 2, the CMTDD recently invested in the
development of technologies to enhance the sophistication of investigator research while minimizing the cost of
access. These technologies: single-cell and spatial transcriptomic analysis, organoid generation and
manipulation, and inhibitor and proteolysis-targeting chimera (PROTAC) synthesis will be integrated into three
Phase 2 CMTDD cores. These investments will enhance the research capabilities of the institution, expand the
translational capacity of its faculty, facilitate the training, mentoring, and career advancement of promising new
faculty, and efficiently drive discovery and development for the improvement of human health in Nebraska and
the nation. Phase 2 RPLs bring a breadth of cutting-edge expertise to the CMTDD. With mentoring and ready
access to CMTDD-supported cores, our RPLs will become self-supporting faculty members invaluable to the
future success of UNMC. Our Phase 2 RPLs share both a passion for exploration of the basic biologic principles
that underly cell homeostasis and a belief that many diseases can be effectively classified and characterized
through detailed genomic, genetic, and molecular analyses that identify drivers and vulnerabilities from which
will emerge unique therapeutic approaches. To realize this vision, the CMTDD will: 1) maintain an Administrative
Core and mentoring program that successfully graduated all but one of its initial RPLs in the first four years of
support; 2) increase research capacity through newly established state-of-the-art scientific cores for single-cell
and spatial transcriptomics, organoid development, and inhibitor and PROTAC synthesis and validation; and 3)
provide low- or no-cost access to these technologies and reagents as an affordable means for increasing the
impact of investigator research.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Ubiquitin E3 ligase FBXO21 regulates cytokine-mediated signaling pathways, but is dispensable for steady-state hematopoiesis.
泛素 E3 连接酶 FBXO21 调节细胞因子介导的信号通路,但对于稳态造血来说是可有可无的。
DOI:
10.1016/j.exphem.2022.08.002
发表时间:
2022
期刊:
Experimental hematology
影响因子:
2.6
作者:
[Wittorf,KarliJ, Weber,KasidyK, Swenson,SamanthaA, Buckley,ShannonM]
通讯作者:
Buckley,ShannonM
DOI:
10.7554/elife.76497
发表时间:
2022-06-17
期刊:
ELIFE
影响因子:
7.7
作者:
[Ray, Suhita, Chee, Linda, Zhou, Yichao, Schaefer, Meg A., Naldrett, Michael J., Alvarez, Sophie, Woods, Nicholas T., Hewitt, Kyle J.]
通讯作者:
Hewitt, Kyle J.
Isolation and Immunodetection of Enzymatic DNA-Protein Crosslinks by RADAR Assay.
通过 RADAR 测定法分离和免疫检测酶促 DNA-蛋白质交联。
DOI:
10.1007/978-1-0716-3373-1_8
发表时间:
2023
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Perry,Megan, Ghosal,Gargi]
通讯作者:
Ghosal,Gargi
Interactome Profiling of DNA Damage Response (DDR) Mediators with Immunoprecipitation-Mass Spectrometry.
使用免疫沉淀-质谱法对 DNA 损伤反应 (DDR) 介质进行相互作用组分析。
DOI:
10.1007/978-1-0716-3373-1_12
发表时间:
2023
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Law,HenryC-H, Noe,Dragana, Woods,NicholasT]
通讯作者:
Woods,NicholasT
DOI:
10.1021/acsinfecdis.9b00527
发表时间:
2020-07-10
期刊:
ACS infectious diseases
影响因子:
5.3
作者:
[Rosenthal MR, Ng CL]
通讯作者:
Ng CL
共 7 条
Pancreatic cancer variant analysis of the All of Us cohort
-
批准号:10660291
-
项目类别:
-
资助金额:$11.51万
-
财政年份:2022
-
负责人:Robert E. Lewis
-
依托单位:
Novel Mechanisms Controlling SCLC Tumor Initiation
-
批准号:10303538
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2021
-
负责人:Robert E. Lewis
-
依托单位:
Novel Mechanisms Controlling SCLC Tumor Initiation
-
批准号:10453763
-
项目类别:
-
资助金额:$20.84万
-
财政年份:2021
-
负责人:Robert E. Lewis
-
依托单位:
Nebraska Center for Molecular Target Discovery and Development
-
批准号:9920161
-
项目类别:
-
资助金额:$227.02万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Nebraska Center for Molecular Target Discovery and Development
-
批准号:10392932
-
项目类别:
-
资助金额:$227.02万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Administrative Core
-
批准号:10392933
-
项目类别:
-
资助金额:$116.89万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Administrative Core
-
批准号:10714237
-
项目类别:
-
资助金额:$50.02万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Administrative Core
-
批准号:10117095
-
项目类别:
-
资助金额:$79.33万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Nebraska Center for Molecular Target Discovery and Development
-
批准号:10117079
-
项目类别:
-
资助金额:$227.02万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Development of Spatial Transcriptomics Capability
-
批准号:10582415
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2018
-
负责人:Robert E. Lewis
-
依托单位:
Novel Effectors of Colon Tumorigenesis
-
批准号:9034446
-
项目类别:
-
资助金额:$30.96万
-
财政年份:2012
-
负责人:Robert E. Lewis
-
依托单位:
Novel Effectors of Colon Tumorigenesis
-
批准号:8627963
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2012
-
负责人:Robert E. Lewis
-
依托单位:
Novel Effectors of Colon Tumorigenesis
-
批准号:8827270
-
项目类别:
-
资助金额:$30.96万
-
财政年份:2012
-
负责人:Robert E. Lewis
-
依托单位:
Novel Effectors of Colon Tumorigenesis
-
批准号:8458937
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2012
-
负责人:Robert E. Lewis
-
依托单位:
PILOT PROJECT 1 UBIQUITIN-MEDIATED REGULATION OF KINASE SUPPRESSOR OF RAS1
-
批准号:8168392
-
项目类别:
-
资助金额:$3.36万
-
财政年份:2010
-
负责人:Robert E. Lewis
-
依托单位:
KSR, a Modifier of Ras Mediated Cell Transformation
-
批准号:6430333
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2002
-
负责人:Robert E. Lewis
-
依托单位:
KSR, a Modifier of Ras-Mediated Cell Transformation
-
批准号:7525658
-
项目类别:
-
资助金额:$26.59万
-
财政年份:2002
-
负责人:Robert E. Lewis
-
依托单位:
KSR, a Modifier of Ras-Mediated Cell Transformation
-
批准号:7686623
-
项目类别:
-
资助金额:$4.05万
-
财政年份:2002
-
负责人:Robert E. Lewis
-
依托单位:
KSR, a Modifier of Ras Mediated Cell Transformation
-
批准号:6621074
-
项目类别:
-
资助金额:$26.17万
-
财政年份:2002
-
负责人:Robert E. Lewis
-
依托单位:
KSR, a Modifier of Ras-Mediated Cell Transformation
-
批准号:8305038
-
项目类别:
-
资助金额:$25.79万
-
财政年份:2002
-
负责人:Robert E. Lewis
-
依托单位:
海外基金